Cullinan Oncology Inc
NASDAQ:CGEM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.75
12.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cullinan Oncology Inc
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.
